ArticleBiological trace element research2026
p-Coumaric Acid Attenuates Lead Acetate-induced Neurotoxicity in Rats by Improving Behavioral Dysfunction and Suppressing Oxidative Stress, Neuroinflammation, Apoptosis, and Plasticity-related Molecular Alterations.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the neuroprotective effects of p-coumaric acid (p-CA) against lead acetate (PbAc)-induced neurotoxicity in rats by focusing on oxidative stress, neuroinflammation, apoptosis, and neuronal plasticity. 35 male rats were randomly assigned to five groups: Control, p-CA (100 mg/kg), PbAc (30 mg/kg), PbAc + p-CA (50 mg/kg), and PbAc + p-CA (100 mg/kg). Treatments were administered orally for 14 days. Behavioral performance was assessed using the open field test (OFT) and elevated plus maze (EPM). Biochemical analyses of brain tissue included the measurement of MDA, GSH, SOD, CAT, and GPx levels. Western blotting was performed to determine the protein expression levels of inflammatory, glial, and synaptic markers, including NF-κB, IL-1β, IL-6, TNF-α, Iba-1, GFAP, PSD-95, and AChE. Quantitative real-time PCR was used to assess the mRNA expression levels of Bax, Bcl-2, Caspase-3, MAP-2, NeuN, and GAP-43. Histological evaluations included hematoxylin-eosin (H&E) staining for neuronal morphology, immunohistochemistry (IHC) for 8-OHdG, GABA, and GFAP, and immunofluorescence (IF) staining for BDNF expression. PbAc exposure caused marked oxidative damage, neuroinflammatory activation, enhanced apoptotic signaling, and impaired neuronal plasticity, accompanied by reduced antioxidant defenses and altered expression of plasticity-related markers. Co-treatment with p-CA significantly ameliorated these biochemical, molecular, and histopathological alterations in a dose-dependent manner. The 100 mg/kg dose of p-CA showed the strongest neuroprotective effect, restoring many parameters close to control levels. Overall, these findings suggest that p-coumaric acid exerts neuroprotective effects against PbAc-induced brain injury by attenuating oxidative stress, neuroinflammation, and apoptosis while supporting neuronal plasticity. Therefore, p-CA may represent a promising natural compound for further investigation in heavy metal-induced neurotoxicity models. However, further studies are required to clarify the upstream molecular signaling pathways involved and to determine whether these protective effects can be maintained under long-term exposure conditions.
Indexed as
Identifiers
42552489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.